Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer – real-world data from a multicenter German patient population
Abstract Background Biliary tract cancers (BTCs) are a heterogeneous group of malignant cancers with an overall poor prognosis. For more than a decade, the standard palliative first-line therapy was cytotoxic chemotherapy with gemcitabine/cisplatin. The results of the TOPAZ-1 and KEYNOTE-966 trials...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-06-01
|
| Series: | Journal of Cancer Research and Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00432-025-06239-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849344642523332608 |
|---|---|
| author | Florian Gerhardt Christian Müller Marino Venerito Jack Chater Raphael Mohr Mara Egerer Udo Lindig Aaron Schindler Sebastian Ebel Janett Fischer Maik Schwarz Sonja Gehring Thomas Berg Florian van Bömmel |
| author_facet | Florian Gerhardt Christian Müller Marino Venerito Jack Chater Raphael Mohr Mara Egerer Udo Lindig Aaron Schindler Sebastian Ebel Janett Fischer Maik Schwarz Sonja Gehring Thomas Berg Florian van Bömmel |
| author_sort | Florian Gerhardt |
| collection | DOAJ |
| description | Abstract Background Biliary tract cancers (BTCs) are a heterogeneous group of malignant cancers with an overall poor prognosis. For more than a decade, the standard palliative first-line therapy was cytotoxic chemotherapy with gemcitabine/cisplatin. The results of the TOPAZ-1 and KEYNOTE-966 trials have now introduced immune checkpoint inhibitors (ICIs) into first-line therapy. Methods Between July 2022 and March 2024, we retrospectively analyzed patients with advanced BTC who were treated with gemcitabine/cisplatin and durvalumab (GCD) at collaborating German university hospitals, tertiary hospitals, and outpatient oncology practices. Results A total of 90 patients were enrolled. The median overall survival (mOS) was 16 months, and the median progression-free survival (mPFS) was 5 months. The overall response rate (ORR) was 11.1%, and the disease control rate (DCR) was 41.1%. A perihilar primary tumor was significantly associated with better mPFS, while age group between 70 and 75 years and performance status of ECOG 2 at treatment initiation were significantly associated with poorer mOS. Adverse events (AEs) occurred in a total of 64% of patients. The most common grade 1 and grade 2 AEs included anemia (23%), thrombocytopenia (16%), neutropenia (10%), nausea (14%), and fatigue (16%). Grade 3 and grade 4 AEs included anemia (10%), thrombocytopenia (5%), and neutropenia (11%). Only one case of immune-mediated hypothyroidism (imAE) was documented. Conclusion Our real-world data support previously reported findings and further validate ICI based therapy as the standard of care for patients with advanced BTCs. |
| format | Article |
| id | doaj-art-6800e98f7a43476fafedc1fc2d0af07b |
| institution | Kabale University |
| issn | 1432-1335 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Springer |
| record_format | Article |
| series | Journal of Cancer Research and Clinical Oncology |
| spelling | doaj-art-6800e98f7a43476fafedc1fc2d0af07b2025-08-20T03:42:37ZengSpringerJournal of Cancer Research and Clinical Oncology1432-13352025-06-01151611010.1007/s00432-025-06239-1Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer – real-world data from a multicenter German patient populationFlorian Gerhardt0Christian Müller1Marino Venerito2Jack Chater3Raphael Mohr4Mara Egerer5Udo Lindig6Aaron Schindler7Sebastian Ebel8Janett Fischer9Maik Schwarz10Sonja Gehring11Thomas Berg12Florian van Bömmel13Division of Hepatology, Department of Medicine II, Leipzig University Medical CenterDepartment of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University HospitalDepartment of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University HospitalMedical Clinic III, Klinikum ChemnitzDepartment of Hepatology and Gastroenterology, Charité University Medicine BerlinDepartment of Hepatology and Gastroenterology, Charité University Medicine BerlinMedical Clinic II, University Hospital JenaDivision of Hepatology, Department of Medicine II, Leipzig University Medical CenterDepartment of Diagnostic and Interventional Radiology, Leipzig University Medical CenterDivision of Hepatology, Department of Medicine II, Leipzig University Medical CenterMVZ SchöneckDepartment of Gastroenterology, University Hospital MarburgDivision of Hepatology, Department of Medicine II, Leipzig University Medical CenterDivision of Hepatology, Department of Medicine II, Leipzig University Medical CenterAbstract Background Biliary tract cancers (BTCs) are a heterogeneous group of malignant cancers with an overall poor prognosis. For more than a decade, the standard palliative first-line therapy was cytotoxic chemotherapy with gemcitabine/cisplatin. The results of the TOPAZ-1 and KEYNOTE-966 trials have now introduced immune checkpoint inhibitors (ICIs) into first-line therapy. Methods Between July 2022 and March 2024, we retrospectively analyzed patients with advanced BTC who were treated with gemcitabine/cisplatin and durvalumab (GCD) at collaborating German university hospitals, tertiary hospitals, and outpatient oncology practices. Results A total of 90 patients were enrolled. The median overall survival (mOS) was 16 months, and the median progression-free survival (mPFS) was 5 months. The overall response rate (ORR) was 11.1%, and the disease control rate (DCR) was 41.1%. A perihilar primary tumor was significantly associated with better mPFS, while age group between 70 and 75 years and performance status of ECOG 2 at treatment initiation were significantly associated with poorer mOS. Adverse events (AEs) occurred in a total of 64% of patients. The most common grade 1 and grade 2 AEs included anemia (23%), thrombocytopenia (16%), neutropenia (10%), nausea (14%), and fatigue (16%). Grade 3 and grade 4 AEs included anemia (10%), thrombocytopenia (5%), and neutropenia (11%). Only one case of immune-mediated hypothyroidism (imAE) was documented. Conclusion Our real-world data support previously reported findings and further validate ICI based therapy as the standard of care for patients with advanced BTCs.https://doi.org/10.1007/s00432-025-06239-1CholangiocarcinomaBiliary tract cancerLiver cancerImmune checkpoint inhibitorReal-world data |
| spellingShingle | Florian Gerhardt Christian Müller Marino Venerito Jack Chater Raphael Mohr Mara Egerer Udo Lindig Aaron Schindler Sebastian Ebel Janett Fischer Maik Schwarz Sonja Gehring Thomas Berg Florian van Bömmel Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer – real-world data from a multicenter German patient population Journal of Cancer Research and Clinical Oncology Cholangiocarcinoma Biliary tract cancer Liver cancer Immune checkpoint inhibitor Real-world data |
| title | Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer – real-world data from a multicenter German patient population |
| title_full | Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer – real-world data from a multicenter German patient population |
| title_fullStr | Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer – real-world data from a multicenter German patient population |
| title_full_unstemmed | Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer – real-world data from a multicenter German patient population |
| title_short | Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer – real-world data from a multicenter German patient population |
| title_sort | treatment with gemcitabine cisplatin and durvalumab for advanced biliary tract cancer real world data from a multicenter german patient population |
| topic | Cholangiocarcinoma Biliary tract cancer Liver cancer Immune checkpoint inhibitor Real-world data |
| url | https://doi.org/10.1007/s00432-025-06239-1 |
| work_keys_str_mv | AT floriangerhardt treatmentwithgemcitabinecisplatinanddurvalumabforadvancedbiliarytractcancerrealworlddatafromamulticentergermanpatientpopulation AT christianmuller treatmentwithgemcitabinecisplatinanddurvalumabforadvancedbiliarytractcancerrealworlddatafromamulticentergermanpatientpopulation AT marinovenerito treatmentwithgemcitabinecisplatinanddurvalumabforadvancedbiliarytractcancerrealworlddatafromamulticentergermanpatientpopulation AT jackchater treatmentwithgemcitabinecisplatinanddurvalumabforadvancedbiliarytractcancerrealworlddatafromamulticentergermanpatientpopulation AT raphaelmohr treatmentwithgemcitabinecisplatinanddurvalumabforadvancedbiliarytractcancerrealworlddatafromamulticentergermanpatientpopulation AT maraegerer treatmentwithgemcitabinecisplatinanddurvalumabforadvancedbiliarytractcancerrealworlddatafromamulticentergermanpatientpopulation AT udolindig treatmentwithgemcitabinecisplatinanddurvalumabforadvancedbiliarytractcancerrealworlddatafromamulticentergermanpatientpopulation AT aaronschindler treatmentwithgemcitabinecisplatinanddurvalumabforadvancedbiliarytractcancerrealworlddatafromamulticentergermanpatientpopulation AT sebastianebel treatmentwithgemcitabinecisplatinanddurvalumabforadvancedbiliarytractcancerrealworlddatafromamulticentergermanpatientpopulation AT janettfischer treatmentwithgemcitabinecisplatinanddurvalumabforadvancedbiliarytractcancerrealworlddatafromamulticentergermanpatientpopulation AT maikschwarz treatmentwithgemcitabinecisplatinanddurvalumabforadvancedbiliarytractcancerrealworlddatafromamulticentergermanpatientpopulation AT sonjagehring treatmentwithgemcitabinecisplatinanddurvalumabforadvancedbiliarytractcancerrealworlddatafromamulticentergermanpatientpopulation AT thomasberg treatmentwithgemcitabinecisplatinanddurvalumabforadvancedbiliarytractcancerrealworlddatafromamulticentergermanpatientpopulation AT florianvanbommel treatmentwithgemcitabinecisplatinanddurvalumabforadvancedbiliarytractcancerrealworlddatafromamulticentergermanpatientpopulation |